聯合生物製藥 United BioPharma
-
不需再和慢性自發性蕁麻疹妥協! 聯亞生技集團創新型IgE單株抗體UB-221優異數據獲國際權威期刊 Journal of Clinical Investigation《臨床研究雜誌》肯定刊登
不需再和慢性自發性蕁麻疹妥協! 聯亞生技集團創新型IgE單株抗體UB-221優異數據獲國際權威期刊 Journal of Clinical Investigation《臨床研究雜誌》肯定刊登不需再和慢性自發性蕁麻疹妥協! 聯亞生技集團創新型IgE單株抗體UB-221優異數據獲國際權威期刊 Journal of Clinical Investigation《臨床研究雜誌》肯定刊登more -
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional CureUnited BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Curemore -
聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准
聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准more -
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital HerpesUnited BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpesmore -
全人單株抗體UB-621用於復發性生殖器皰疹病患2期臨床試驗獲中國NMPA核准執行
全人單株抗體UB-621用於復發性生殖器皰疹病患2期臨床試驗獲中國NMPA核准執行全人單株抗體UB-621用於復發性生殖器皰疹病患2期臨床試驗獲中國NMPA核准執行more -
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infectionUnited BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infectionmore